Literature DB >> 29946783

Targeting Metabolic Cross Talk between Cancer Cells and Cancer-Associated Fibroblasts.

Jin G Jung1, Anne Le2.   

Abstract

KEY POINTS: Although tumorigenesis has classically been regarded as a genetic disease of uncontrolled cell growth, the importance of the tumor microenvironment (TME) is continuously emphasized by the accumulating evidence that cancer growth is not simply dependent on the cancer cells themselves [1, 2] but also dependent on angiogenesis [3–6], inflammation [7, 8], and the supporting roles of cancer-associated fibroblasts (CAFs) [9, 10]. After the discovery that CAFs are able to remodel the tumor matrix within the TME and provide the nutrients and chemicals to promote cancer cell growth [11], many studies have aimed to uncover the cross talk between cancer and CAFs. Moreover, a new paradigm in cancer metabolism shows how cancer cells act like “metabolic parasites” to uptake the high-energy metabolites, such as lactate, ketone bodies, free fatty acid, and glutamine from supporting cells, including CAFs and cancer-associated adipocytes (CAAs) [12, 13]. This chapter provides an overview of the metabolic coupling between CAFs and cancer to further define the therapeutic options to disrupt the CAF-cancer cell interactions.

Entities:  

Keywords:  Cancer therapy; Cancer-associated adipocytes; Cancer-associated fibroblasts; Metabolism; Metabolites; Tumor microenvironment

Mesh:

Year:  2018        PMID: 29946783     DOI: 10.1007/978-3-319-77736-8_12

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  82 in total

1.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

2.  Leptin mediates tumor-stromal interactions that promote the invasive growth of breast cancer cells.

Authors:  Ines Barone; Stefania Catalano; Luca Gelsomino; Stefania Marsico; Cinzia Giordano; Salvatore Panza; Daniela Bonofiglio; Gianluca Bossi; Kyle R Covington; Suzanne A W Fuqua; Sebastiano Andò
Journal:  Cancer Res       Date:  2012-01-26       Impact factor: 12.701

3.  Evidence for a stromal-epithelial "lactate shuttle" in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts.

Authors:  Diana Whitaker-Menezes; Ubaldo E Martinez-Outschoorn; Zhao Lin; Adam Ertel; Neal Flomenberg; Agnieszka K Witkiewicz; Ruth C Birbe; Anthony Howell; Stephanos Pavlides; Ricardo Gandara; Richard G Pestell; Federica Sotgia; Nancy J Philp; Michael P Lisanti
Journal:  Cell Cycle       Date:  2011-06-01       Impact factor: 4.534

4.  Lactate is a mediator of metabolic cooperation between stromal carcinoma associated fibroblasts and glycolytic tumor cells in the tumor microenvironment.

Authors:  Yanique I Rattigan; Brijesh B Patel; Ellen Ackerstaff; George Sukenick; Jason A Koutcher; John W Glod; Debabrata Banerjee
Journal:  Exp Cell Res       Date:  2011-12-08       Impact factor: 3.905

5.  Lactate utilization by brain cells and its role in CNS development.

Authors:  José M Medina; Arantxa Tabernero
Journal:  J Neurosci Res       Date:  2005 Jan 1-15       Impact factor: 4.164

Review 6.  Metabolic interplay between glycolysis and mitochondrial oxidation: The reverse Warburg effect and its therapeutic implication.

Authors:  Minjong Lee; Jung-Hwan Yoon
Journal:  World J Biol Chem       Date:  2015-08-26

7.  Molecular signatures suggest a major role for stromal cells in development of invasive breast cancer.

Authors:  Theresa Casey; Jeffrey Bond; Scott Tighe; Timothy Hunter; Laura Lintault; Osman Patel; Jonathan Eneman; Abigail Crocker; Jeffrey White; Joseph Tessitore; Mary Stanley; Seth Harlow; Donald Weaver; Hyman Muss; Karen Plaut
Journal:  Breast Cancer Res Treat       Date:  2008-03-29       Impact factor: 4.872

Review 8.  Ketone bodies as signaling metabolites.

Authors:  John C Newman; Eric Verdin
Journal:  Trends Endocrinol Metab       Date:  2013-10-18       Impact factor: 12.015

9.  Mitochondria as new therapeutic targets for eradicating cancer stem cells: Quantitative proteomics and functional validation via MCT1/2 inhibition.

Authors:  Rebecca Lamb; Hannah Harrison; James Hulit; Duncan L Smith; Michael P Lisanti; Federica Sotgia
Journal:  Oncotarget       Date:  2014-11-30

Review 10.  Metabolic Cooperation and Competition in the Tumor Microenvironment: Implications for Therapy.

Authors:  Seema Gupta; Amrita Roy; Bilikere S Dwarakanath
Journal:  Front Oncol       Date:  2017-04-12       Impact factor: 6.244

View more
  6 in total

Review 1.  Sculpting tumor microenvironment with immune system: from immunometabolism to immunoediting.

Authors:  Y-R Yu; P-C Ho
Journal:  Clin Exp Immunol       Date:  2019-04-01       Impact factor: 4.330

Review 2.  The Metabolic Interplay between Cancer and Other Diseases.

Authors:  Anne Le; Sunag Udupa; Cissy Zhang
Journal:  Trends Cancer       Date:  2019-11-21

Review 3.  Mucins reprogram stemness, metabolism and promote chemoresistance during cancer progression.

Authors:  Saravanakumar Marimuthu; Sanchita Rauth; Koelina Ganguly; Chunmeng Zhang; Imayavaramban Lakshmanan; Surinder K Batra; Moorthy P Ponnusamy
Journal:  Cancer Metastasis Rev       Date:  2021-04-04       Impact factor: 9.237

4.  Development and Validation of Lactate Metabolism-Related lncRNA Signature as a Prognostic Model for Lung Adenocarcinoma.

Authors:  Shijie Mai; Liping Liang; Genghui Mai; Xiguang Liu; Dingwei Diao; Ruijun Cai; Le Liu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-29       Impact factor: 5.555

Review 5.  Metabolic reprogramming and crosstalk of cancer-related fibroblasts and immune cells in the tumor microenvironment.

Authors:  Yifei Zhu; Xinyan Li; Lei Wang; Xiwei Hong; Jie Yang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-15       Impact factor: 6.055

Review 6.  The role of cancer stromal fibroblasts in mediating the effects of tobacco-induced cancer cell growth.

Authors:  Zai-Zai Cao; Yin-Jie Ao; Shui-Hong Zhou
Journal:  Cancer Cell Int       Date:  2021-12-25       Impact factor: 5.722

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.